Communiqués Profound Medical Corp.

Actions

PRN

CA74319B5027

Equipement et technologie médicale avancés

Marché Fermé - Toronto S.E. 22:00:00 17/08/2026			Varia. 5j.	Varia. 1 janv.
9,200 ^CAD	0,00%		-9,80%	-14,58%

14/08	Profound Medical nomme Matthew Sobczyk au poste de directeur financier par intérim	MT
14/08	Profound Medical nomme Matthew Sobczyk au poste de directeur financier par intérim suite au départ de Rashed Dewan	MT

Communiqués

17/08	Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’	AQ
14/08	Profound Medical Announces Management Change	AQ
13/08	Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey	AQ
06/08	Profound Medical Reports Second Quarter 2026 Financial Results	AQ
27/07	Robotic Radical Prostatectomy Comes Up 'Short' in CAPTAIN Trial	AQ
24/07	Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial	AQ
16/07	Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow	AQ
15/07	Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026	AQ
14/05	Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026	AQ
14/05	Profound Medical Annual General and Special Meeting of Shareholders Voting Results	NE
08/05	Profound Medical : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Profound Medical Reports Strong First Quarter 2026 Financial Results	AQ
07/05	Profound Medical : Investor Presentation (Profound Investor Presentation May 2026 ver1)	PU
21/04	Profound Medical : Investor Presentation (Profound Investor Presentation April 2026 ver9final)	PU
20/04	Profound Medical : Investor Presentation (Profound Investor Presentation April 2026 ver8final)	PU
17/04	Profound Medical to Release First Quarter 2026 Financial Results on May 7 Conference Call to Follow	AQ
16/04	Profound Medical : FY 2025 Management Information Circular	PU
16/04	Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow	AQ
14/04	Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference	AQ
02/04	Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO to be featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting	AQ
01/04	Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting	AQ
30/03	Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure Milestone	AQ
27/03	Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone	AQ
13/03	CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence	AQ
09/03	Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24	AQ